Metrics to compare | SLGL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLGLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −260.0x | 6.6x | −0.4x | |
PEG Ratio | −2.83 | 0.03 | 0.00 | |
Price/Book | 5.3x | 1.8x | 2.6x | |
Price / LTM Sales | 14.7x | 2.2x | 3.0x | |
Upside (Analyst Target) | 121.2% | 27.5% | 50.8% | |
Fair Value Upside | Unlock | 11.6% | 9.4% | Unlock |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.